Department of Pharmacology, Faculty of Pharmacy, University of Hacettepe, Sihhiye, Ankara, Turkey.
J Cardiovasc Pharmacol. 2010 Nov;56(5):498-505. doi: 10.1097/FJC.0b013e3181f4838b.
This study aimed to examine the effect of monocrotaline (MCT)-induced pulmonary hypertension on electrical field stimulation (EFS)-mediated relaxation in rings of rat main pulmonary artery and to see whether treatment with atorvastatin or L-arginine would prevent the action of MCT. Rats were killed 21 days after MCT injection (60 mg/kg), and the main pulmonary arteries were isolated. EFS (40 V, 0.2 milliseconds, 5 seconds, 10 Hz)-induced relaxations in vessels precontracted with phenylephrine (10(-6) to 3 × 10(-6) M) were abolished in MCT-injected group compared with control group. Treatment of MCT group with atorvastatin (10 mg/kg, orally) completely, whereas treatment with L-arginine (500 mg/kg, intraperitoneally) partially but significantly prevented the inhibition. Similarly, acetylcholine (10(-9) to 3 × 10(-5) M)-evoked relaxations that were markedly inhibited in MCT-group were also protected from inhibition after pretreatment with atorvastatin or L-arginine. Responses to endothelium-independent relaxants sodium nitroprusside (10(-9) to 10(-5) M), pinacidil (10(-10) to 10(-4) M), and papaverine (10(-8) to 10(-4) M) were unaltered in MCT-induced pulmonary hypertensive rats. The present findings suggest that MCT-induced pulmonary hypertension inhibits the EFS-mediated relaxation through suppression of endothelial NO production. Reversal of this inhibition by atorvastatin treatment presumably results from stimulation of endothelial nitric oxide synthase expression. Relatively weak protection elicited by L-arginine might be secondary to impaired endothelial nitric oxide synthase activity caused by MCT-induced pulmonary hypertension.
这项研究旨在探讨单硝酸异山梨酯(MCT)诱导的肺动脉高压对大鼠主肺动脉环电刺激(EFS)介导的舒张的影响,并观察阿托伐他汀或 L-精氨酸治疗是否能预防 MCT 的作用。在 MCT 注射后 21 天(60mg/kg)处死大鼠,并分离主肺动脉。与对照组相比,MCT 注射组中预先用苯肾上腺素(10(-6)至 3 × 10(-6) M)收缩的血管中,EFS(40V、0.2ms、5s、10Hz)诱导的舒张作用被消除。阿托伐他汀(10mg/kg,口服)治疗 MCT 组完全,而 L-精氨酸(500mg/kg,腹腔内)治疗部分但显著地预防了抑制作用。同样,在 MCT 组中明显抑制的乙酰胆碱(10(-9)至 3 × 10(-5) M)诱导的舒张作用也在阿托伐他汀或 L-精氨酸预处理后受到保护,免受抑制。MCT 诱导的肺动脉高压大鼠对内皮非依赖性舒张剂硝普钠(10(-9)至 10(-5) M)、匹那地尔(10(-10)至 10(-4) M)和罂粟碱(10(-8)至 10(-4) M)的反应没有改变。本研究结果表明,MCT 诱导的肺动脉高压通过抑制内皮一氧化氮产生抑制 EFS 介导的舒张。阿托伐他汀治疗逆转这种抑制作用可能是由于刺激内皮型一氧化氮合酶表达所致。L-精氨酸引起的相对较弱的保护作用可能是由于 MCT 诱导的肺动脉高压引起的内皮型一氧化氮合酶活性受损所致。